SKSree S. Kolli

Sree S. Kolli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sree S. Kolli has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Steven Richard Feldman

    Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina

    7 shared publications
  • Abigail Cline

    Department of Dermatology, New York Medical College, New York, NY.

    4 shared publications
  • Aditi Senthilnathan

    Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina

    4 shared publications
  • Steven R. Feldman

    Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina; Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina; Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina

    4 shared publications
  • Adrian Pona

    Wake Forest School of Medicine

    3 shared publications
  • Rita O. Pichardo

    Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA

    3 shared publications

Latest Publications

  • Evidence-Based Management

    by Adrian Pona, Abigail Cline, Sree S. Kolli, Sarah L. Taylor, Steven R. Feldman

    • 1 March 2020
      • Vol. 105  (3) , E32-E33

    Is There an Association Between Hidradenitis Suppurativa and Fibromyalgia?

    by Sree S. Kolli, Kyle A. Habet, Alejandra Herrera, Wasim Haidari, Rita O. Pichardo


  • Hidradenitis suppurativa has an enormous impact on patients' lives

    by Sree S. Kolli, Aditi Senthilnathan, Leah A. Cardwell, Irma M. Richardson, Steven R. Feldman, Rita O. Pichardo


  • Adherence in Atopic Dermatitis

    by Sree S. Kolli, Adrian Pona, Abigail Cline, Lindsay C. Strowd, Steven R. Feldman


  • Review of Graft-Versus-Host Disease

    by Vignesh Ramachandran, Sree S. Kolli, Lindsay C. Strowd


  • Emotional Well-Being Is Impaired in Hidradenitis Suppurativa Patients

    by Aditi Senthilnathan, Sree S. Kolli, Leah A. Cardwell, Irma M. Richardson, Steven R. Feldman, Rita O. Pichardo

    Background: Hidradenitis suppurativa (HS) is a chronic inflammatory condition. Objective: To measure emotional well-being in HS patients and compare to other populations, assess if there is an effect of disease severity on emotional well-being, and determine if emotional well-being is correlated with quality of life and depression. Methods: A total of 153 HS subjects were recruited, and 66 Positive and Negative Affect Schedule (PANAS) surveys assessing emotional well-being were completed. Norms for comparison populations (disease-free undergraduates and adults) were used. A validated self-assessment tool was used to determine disease severity. Subjects completed the Patient Health Questionnaire-9 (PHQ-9) and Dermatology Life Quality Index (DLQI) to examine depression and quality of life, respectively. Results: HS subjects had lower positive affect than undergraduates and higher negative affect than adults. There were no differences in PANAS scores by Hurley stage (p > 0.05). PANAS scores for HS subjects correlated with worse quality of life (r = 0.66, p < 0.00001) and depression (r = 0.74, p < 0.00001). Conclusion: HS patients have poor emotional well-being. PANAS scores correlated with worse quality of life and depression. Providing appropriate resources and treatments may be beneficial for HS patients.


  • Depression in hidradenitis suppurativa

    by A. Senthilnathan, S.S. Kolli, L.A. Cardwell, I.M. Richardson, S.R. Feldman, R.O. Pichardo


  • A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data

    by Sree S. Kolli, Anna L. Kepley, Abigail Cline, Steven R. Feldman

    Introduction: Psoriasis is a chronic, inflammatory condition whose management can include oral medications and injectable biologics. Safety data of these various treatment options are important to consider when choosing the right treatment for the patient. Areas covered: This review evaluates the safety of newer treatments approved for psoriasis, including interleukin-(IL)-17 inhibitors, IL-23/p19 inhibitors, ustekinumab, certolizumab pegol and apremilast, using phases III and IV clinical trial data. Expert opinion: Even as treatment of psoriasis becomes more effective and safer, it is important to recognize both common and uncommon adverse effects of treatment. Common adverse effects are similar across treatment options, including upper respiratory infection and injection-site reaction. Serious adverse effects occur less frequently and may be specific to the psoriasis treatment option, such as inflammatory bowel disease and candida infections with IL-17 inhibitors, tuberculosis with certolizumab pegol, and psychiatric events with apremilast. While IL-23/p19 inhibitors may have a slightly better safety profile than other biologics, long-term data are limited. Patients should be aware of both the common AEs to prevent premature discontinuation of treatment and the rare AEs to monitor for development of serious symptoms. The conclusions that can be drawn from clinical trial safety data are limited given that many clinical trials are not large enough to detect rare safety events, and there may be differences in safety experienced in clinical practice that are not well documented. Data from registries provide important complementary information on long-term safety but there are limitations including a lack of randomized assignment between drug treatments.


  • Open Access

    Treatment-resistant prurigo nodularis

    by Sree S Kolli, Wasim Haidari, Steven R Feldman

    Treatment-resistant prurigo nodularis Sree S Kolli,1 Wasim Haidari,1 Steven R Feldman1–31Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA Dear editorKowalski et al describe various treatment approaches to achieve better outcomes in treatment-resistant prurigo nodularis in an article entitled, “Treatment-resistant prurigo nodularis: challenges and solutions.”1 Many excellent approaches are suggested, but the issue of nonadherence to topical therapies may be an overlooked issue commonly contributing to “treatment-resistance.” Often, in the face of “resistant” disease, patients may be prescribed more complicated or risky treatment regimens that make adherence even more difficult. Such strategies may not be the most effective ones when poor adherence underlies seemingly treatment-resistant prurigo nodularis.Treatment-resistance can often be overcome by measures that improve adherence. Even patients with severe, refractory atopic dermatitis respond rapidly to midpotency topical corticosteroids applied in the inpatient setting. Prurigo nodularis is often secondary to atopic dermatitis and psoriasis. In patients with atopic dermatitis or psoriasis that was “resistant” to topical corticosteroids, all patients treated with an easy to use topical corticosteroid spray improved rapidly when coupled with adherence promoting measures (telephone reminders, patient education and frequent office visits). Adherence to topical treatments is bad in the short-term and abysmal in the long-term.2–4 Perhaps one of the best approaches when faced with treatment-resistant disease is to simplify the treatment regimen and encourage good use of treatment, or better yet, bring patients in to assure the treatment is administered.


  • Even mild hidradenitis suppurativa impairs quality of life

    by A. Senthilnathan, S.S. Kolli, L.A. Cardwell, I.M. Richardson, S.R. Feldman, R.O. Pichardo